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Abstract
Background: Canine distemper virus (CDV) is a major pathogen of dogs and wild carnivores worldwide. In
Switzerland, distemper in domestic dogs is rarely reported. In recent years, the import of dogs from Eastern Europe
to Switzerland has steadily increased. In the present study, we describe a distemper outbreak in 15 rescue dogs that
were imported from Hungary to Switzerland by an animal welfare organisation. The data on vaccination and
medical history were recorded (14 dogs), and the samples were collected to investigate CDV and vector-borne
infections (13 dogs) and canine parvovirus infection (12 dogs). The dogs were monitored for six months.
Results: One dog was euthanised directly after import. Thirteen dogs showed clinical signs after arrival, i.e.,
diarrhoea (57 %), coughing (43 %) and nasal and/or ocular discharge (21 %); radiographic findings that were
compatible with bronchopneumonia were present in four dogs. CDV infection was diagnosed in 11 dogs (85 %);
10 dogs (91 %) tested PCR-positive in conjunctival swabs. Vector-borne infections (Babesia spp., Leishmania
infantum, Dirofilaria immitis) were found in 4 dogs (31 %). Three dogs were hospitalized, and six dogs received
ambulatory therapy for up to two months until recovery. None of the dogs developed neurological disease. CDV
shedding was detected for a period of up to four months. Because dogs were put under strict quarantine until CDV
shedding ceased, CDV did not spread to any other dogs. The CDV isolates showed 99 % sequence identity in the
HA gene among each other and belonged to the Arctic-like lineage of CDV.
Conclusions: The present study highlights the imminent risks of spreading contagious viral and vector-borne infections
through the non-selective import of sick dogs and dogs with incomplete vaccination from Eastern Europe. CDV shedding
was detected for several months after the cessation of clinical signs, which emphasised the roles of asymptomatic carriers
in CDV epidemiology. A long-term follow-up using sensitive PCR and strict quarantine measures is of upmost importance
in preventing the spread of infection. Dog owners and animal welfare organisations should be educated regarding the
importance of complete vaccinations and the impact of dog imports on the spread of viral and vector-borne pathogens.
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Background
Canine distemper virus (CDV) is one of the most im-
portant viral pathogens in domestic dogs and causes
high morbidity and mortality worldwide, particularly in
unvaccinated dogs or dogs with incomplete vaccination
[1]. CDV is a small, enveloped RNA virus that belongs
to the family Paramyxoviridae and the genus Morbillivirus
[2]. CDV has a wide natural host range that includes a
variety of terrestrial carnivores [2]. Dogs are thought to be
the major reservoir host for CDV [3, 4]. Infection occurs
by direct contact with oronasal secretions of infected
animals [5]; indirect transmission plays only a minor role
in CDV epidemics because the virus is quickly inactivated
in the environment [6].
The course of the CDV infection is strongly dependent
on the immune response in infected animals [7]. In this
context, vaccination is critically important. Dogs that de-
velop an adequate immune response can clear the virus
from most tissues, whereas in dogs that show an inter-
mediate immune response, CDV infects the epithelial
tissues and induces clinical signs. In dogs that have a
weak immune response, CDV disseminates to various
tissues, and the clinical signs are usually severe with the
persistence of the virus until death [8]. Invasion of the
central nervous system occurs when viraemia is suffi-
ciently high [9, 10]. More than 50 % of all CDV infec-
tions are perceived to be subclinical [11]. In clinically
affected dogs, the disease usually starts with fever and a
serous-to-mucopurulent conjunctivitis, followed by a dry
to productive cough, depression, anorexia, vomiting and
diarrhoea [1]. Neurological signs usually develop within
one to three weeks after recovery from systemic illness,
but can occur weeks to months later [12].
Since the introduction of highly protective CDV
modified live virus (MLV) vaccines more than 60 years
ago [13], the incidence of CDV infection in com-
pletely vaccinated dogs has decreased [8]. However, in
regions with a low proportion of vaccinated dogs, in
stray dogs and in shelter environments, the incidence
of CDV epidemics is high. In Switzerland, the last
CDV epidemic in domestic dogs occurred in 1984–
1985; this outbreak was suspected to be attributed to
an inadequate vaccination rate in the Swiss dog popu-
lation at that time [14]. Furthermore, a CDV epi-
demic associated with high morbidity and mortality
commenced in the spring of 2009 in wild carnivores
in Switzerland [15]. The latter was perceived to be
part of a large transnational outbreak that spread
from Eastern to Western Europe. Only one domestic
dog was affected in Switzerland during this outbreak
[15]. Remarkably, the 2-year-old mixed breed dog
died of a CDV-associated neurological disease, al-
though it had received the standard anti-CDV vaccin-
ation protocol.
According to the Animal Identity Service (ANIS) in
Switzerland, the import of dogs increased by 23 % within
one year (2011–2012) [16]. The imported dogs com-
prised primarily stray dogs that were adopted by animal
welfare organizations or pure breed dogs to meet the
increasing demand of miniature breeds in Western
Europe. In the present study, we report on a distemper
outbreak in rescue dogs that had been imported from
Hungary to Switzerland. The study provides data on vac-
cination, medical history, clinical examinations and diag-
nostic imaging of the dogs and CDV testing, testing for
canine parvovirus (CPV) and vector-borne infections.
Additionally, the study gives prospectively collected
follow-up data on the treatment, clinical course and out-
come of the infections and the period of CDV shedding.
Finally, a molecular characterization of the CDV isolates
was performed.
Results
Import and clinical history of the dogs
A group of 15 rescue dogs that derived from a shelter in
Kecskemét, Hungary, was imported to Switzerland in
October 2013. One dog was euthanised within several
days of import because of clinical deterioration; no data
regarding this dog were available. The other 14 dogs
comprised nine female (5 spayed) and five male (4 cas-
trated) mixed breed dogs, aged 6 months to 8 years old,
and weighing 5 kg to 30 kg (Table 1). All of the dogs
had received rabies vaccination (Rabisin®, Biokema SA,
Crissier, Switzerland) six to 33 weeks before import
and deworming (containing Praziquantel, Pyrantel and
Fenbendazol, Uniwerm®, PROVET, Beograd, Serbia)
seven to nine days before their arrival in Switzerland.
Additionally, the dogs had been vaccinated with one shot
of a combined MLV vaccine containing CDV, Canine
Adenovirus-2, CPV, Leptospira spp. and canine Parain-
fluenzavirus (Biocan® DHPPi & L, Table 1), either seven to
eight days (Dogs 1 to 6 and 8 to 14) or one month prior to
arrival in Switzerland (Dog 7); Dog 12 had been revacci-
nated in Switzerland one week prior to sample collection
for CDV PCR (Table 1). After arrival on October 22, 2013,
the rescue dogs were directly distributed to 14 private
households throughout Switzerland (Table 1, Fig. 1). Seven
dogs (Dogs 3, 6, 7, 8, 9, 13 and 14) were placed in multi-
dog households. After arrival, the new owners observed
clinical signs in 13 of the 14 dogs (Table 1), i.e., diarrhoea
(57 %), coughing (43 %), nasal and/or ocular discharge
(21 %), vomiting (14 %), gagging (14 %), lameness (14 %),
apathy and sneezing (each 7 %). Because of these
symptoms, five dogs (Dogs 1, 2, 3, 4 and 8) were
presented to private veterinarians within one week of
arrival. Three of these dogs (Dogs 1, 2 and 3) were
subsequently referred to small animal clinics for additional
investigations.
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Table 1 Signalment, vaccination history, anamnesis, clinical examination and therapy of the 14 rescue dogs
Dog1 Town2 Gender3 Age4 Breed CDV
vaccination
Symptoms after
arrival (22.10.13)
Date of CE7 Findings at CE7 Therapy8
Dog 1 Aesch fs 2 y Mixed breed 15.10.135 Diarrhoea 28.10.13 Fever, ocular/nasal discharge,
coughing, tachypnoea
Infusion, amoxicillin/clavulanic
acid (iv, po), inhalation
Dog 2 Widnau f 8 m Mixed breed 15.10.135 Diarrhoea, coughing,
ocular/nasal discharge
5.11.13 Fever, ocular/nasal discharge,
coughing, dehydration,
increased inspiratory lung
sounds, fluid-filled bowel
loops
Amoxicillin/clavulanic acid (po),
tobramycin eye drops
Dog 3 Hettiswil fs 2 y Mixed breed 15.10.135 Apathy, coughing,
nasal discharge
22.10.13 Fever, paleness, purulent-
bloody nasal discharge,
increased inspiratory lung
sounds, diarrhoea
Infusion, amoxicillin/clavulanic acid
(iv, po), marbofloxacine (iv, po),
imidocarb diproprionate (sc)
Dog 4 Niederglatt mc 3 y Mixed breed 15.10.135 Diarrhoea, coughing,
gagging
22.10.13 Fever, purulent ocular
discharge, coughing, increased
inspiratory lung sounds,
conjunctivitis
Infusion, amoxicillin/
clavulanic acid (iv, po),
allopurinol, inhalation
Dog 5 Aadorf m 6 m Mixed breed 15.10.135 None 5.11.13 Fluid-filled bowel loops Amoxicillin/clavulanic acid
(po), metronidazole (po),
diet, deworming
Dog 6 Unterkulm f 6 m Mixed breed 15.10.135 Diarrhoea, sneezing 5.11.13 Conjunctivitis, fluid-filled
bowel loops
Amoxicillin/clavulanic acid (po)
Dog 7 Niedergösgen f 7 m Mixed breed 18.09.135 Diarrhoea, coughing,
gagging
5.11.13 Coughing, increased inspiratory
lung sounds
Amoxicillin/clavulanic acid (po)
Dog 8 Urtenen-Schönbühl f 8 y Mixed breed 14.10.135 Coughing, lameness 23.10.13 Paleness, cachexia, otitis
externa
Doxycycline (po), ear drops
(Aurizon®), imidocarb
diproprionate (sc)
Dog 9 Biel fs 1y Mixed breed 15.10.135 Vomiting 6.11.13 Mucous vaginal discharge Unknown
Dog 10 Rheinsulz mc 3 y Mixed breed 14.10.135 Diarrhoea, nasal
discharge
7.11.13 Conjunctivitis, purulent/
mucous ocular/nasal
discharge
Doxycycline (po)
Dog 11 Zullwil fs 2 y Mixed breed 15.10.135 Lameness 6.11.13 Lameness None
Dog 12 Küsnacht fs 2y Mixed breed 14.10.135, 5.11.136 Vomiting 24.10.13 Normal None
Dog 13 Meiringen mc 3 y Mixed breed 15.10.135 Diarrhoea 12.11.13 Normal None
Dog 14 Rufi mc 2 y Mixed breed 15.10.135 Diarrhoea, coughing - - Antibiotic injection9 (sc)
1CDV positive dogs (at first presentation) are shown in bold, no clinical examination could be performed in Dog 14 due to aggressive behaviour; 2see also Fig. 1; 3m male intact, mc male castrated, f female intact, fs
female spayed; 4y year, m month(s); 5vaccination with Biocan DHPPi & L; 6vaccination with Nobivac DHPPi; 7CE clinical examination; 8po per os, iv intravenous, sc subcutaneously; 9 the antibiotic compound used in
Dog 14 was unknown
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Clinical examination findings
Clinical examinations were performed on Dogs 1 to 13
(Table 1); Dog 14 could not be examined because of ag-
gressive behaviour. The clinical examinations revealed
mucous, purulent or bloody ocular and/or nasal dis-
charge (39 %), fever (31 %), coughing (31 %), inspiratory
increased lung sounds (31 %), conjunctivitis (23 %),
fluid-filled bowel loops (23 %), paleness (15 %), and
lameness, tachypnoea, diarrhoea, dehydration, cachexia,
otitis externa and vaginal discharge in single dogs
(Table 1). The clinical examinations were unremarkable
in Dogs 12 and 13.
Haematology and blood biochemistry
Haematology and blood biochemistry results were avail-
able for 13 dogs (Tables 2 and 3), 11 of which were
CDV-PCR positive (Dogs 1 to 11, see below). At initial
presentation, anaemia (9/13, 69 %), leucocytosis (8/13,
62 %), eosinophilia (8/11, 73 %), neutrophilia (6/11,
55 %) and monocytosis (5/12, 42 %) were common
(Table 2). Dogs 3 and 4 showed severe pancytopenia and
moderate bicytopenia, respectively; both were CDV
PCR-positive, co-infected with Babesia spp. (Dog 3) or
positive for anti-Leishmania infantum antibodies (Dog 4,
see below), and they exhibited fever, increased inspira-
tory lung sounds, purulent ocular and nasal discharge
and radiographic signs that were compatible with bron-
chopneumonia (Tables 1 to 5). Dog 8 showed slight
anaemia and leucopenia (Table 2); this animal was
co-infected with CDV and Babesia spp. (Tables 4 and 5).
Dog 13 showed a pronounced eosinophilia (Table 2); this
animal was CDV-PCR negative but Dirofilaria immitis
positive (Tables 4 and 5). Blood biochemistry results re-
vealed only unspecific changes in the dogs (Table 3).
Radiographic examinations and echocardiography
The radiographic examinations of the thorax revealed
moderate-to-severe interstitial lung changes with vari-
able bronchial thickening in four dogs (Dogs 1 - 4). The
changes were generalised and most pronounced in the
dorsal (Dog 2), perihilar (Dogs 2 and 4) and caudal lung
areas (Dog 3, Fig. 2). The radiographic findings were
compatible with bronchopneumonia in all four dogs,
and all of the dogs tested CDV PCR-positive. The thor-
acic radiographs of Dog 13 revealed mild right-sided car-
diomegaly and mild generalised bronchointerstitial lung
changes; echocardiography showed mild tricuspid and
aortic regurgitation but no signs of pulmonary hyperten-
sion or right ventricular pressure overload. Dog 13
tested D. immitis-positive but was negative for CDV.
CDV PCR and sequencing results
Eleven of the 13 dogs tested CDV PCR-positive during
the initial examination (Table 4). The positive PCR re-
sults were most commonly obtained from conjunctival
swabs (10 of the 11 CDV-positive dogs, Table 4). The
vaccine-specific real-time reverse transcription (RT)-
quantitative (q)PCR was negative for all ten dogs that
were tested, which supports the finding of infection with
a wild-type CDV strain. All three vaccines that were tested
(Biocan® DHPPi & L, Bioveta, Ivanovice na Hané, Czech
Republic; Nobivac® DHHPi, MSD Animal Health, Luzern,
Switzerland; Canigen® SHA2PPi, Vibac, Glattbrugg,
Switzerland) exhibited a positive PCR result. In gel elec-
trophoresis of the PCR products, a appropriate-sized band
was detected for all ten dogs, as were the three vaccines,
as expected [17]. The sequence of the amplification prod-
uct of the Biocan® DHPPi & L vaccine used in the dogs of
the present study was clearly distinct from the sequence
Fig. 1 Map of Switzerland showing the geographical distribution of the rescue dogs. Numbers 1 to 14 indicate the location of the 14 dogs
(see also Table 1)
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Table 2 Haematology results of 13 rescue dogs at first presentation
Dog1 Date PCV2 (Ref3) % Leuc4 (Ref3) ×
103/μl
Plat5 (Ref3) ×
103/μl
Band Neutro6 (Ref3) ×
103/μl
Segm Neutro7 (Ref3) ×
103/μl
Lymph8 (Ref3) ×
103/μl
Mono9 (Ref3) ×
103/μl
Eos10 (Ref3) ×
103/μl
Baso11 (Ref3) ×
103/μl
Dog 1 28.10.13 32 (42–55) 5.6 (4.7–11.3) 131 (130–394) 0.06 (−0.08) 4.11 (2.5–7.4) 1.07 (1.2–3.4) 0.37 (0.2–0.9) 0.03 (0.1–1.3) 0 (−0.08)
Dog 2 5.11.13 34 (42–55) 11.8 (4.7–11.3) 157 (130–394) 0 (−0.08) 8.7 (2.5–7.4) 0.7 (1.2–3.4) 0.78 (0.2–0.9) 1.57 (0.1–1.3) 0.02 (−0.08)
Dog 3 23.10.13 28 (39–57) 1.03 (6.0–12.0) 17 (150–400) 0.33 (−0.3) 0.25 (3.0–11.5) 0.28 (1.0–4.8) 0.17 (0.15–1.4) 0 (0.1–1.3) 0 (−0.04)
Dog 4 22.10.13 36 (42–57) 9.9 (5.7–12.4) 88 (200–400)
Dog 5 5.11.13 33 (42–55) 17.9 (4.7–11.3) 341 (130–394) 0 (−0.08) 13.1 (2.5–7.4) 1.67 (1.2–3.4) 1.43 (0.2–0.9) 1.64 (0.1–1.3) 0.05 (−0.08)
Dog 6 5.11.13 36 (42–55) 13.2 (4.7–11.3) 131 (130–394) 0 (−0.08) 9.23 (2.5–7.4) 2.31 (1.2–3.4) 1.1 (0.2–0.9) 0.51 (0.1–1.3) 0.05 (−0.08)
Dog 7 5.11.13 45 (42–55) 14.3 (4.7–11.3) 430 (130–394) 0 (−0.08) 7.84 (2.5–7.4) 2.03 (1.2–3.4) 1.36 (0.2–0.9) 2.89 (0.1–1.3) 0.13 (−0.08)
Dog 8 23.10.13 33 (37–55) 5.44 (6.0–17.0) 619 (150–500) 0.5 (1.0–4.8) 0.1 (0.1–1.8)
Dog 9 6.11.13 42 (42–55) 18.1 (4.7–11.3) 146 (130–394) 0 (−0.08) 12.61 (2.5–7.4) 2.09 (1.2–3.4) 1.33 (0.2–0.9) 1.96 (0.1–1.3) 0.06 (−0.08)
Dog 10 7.11.13 31 (42–55) 9.9 (4.7–11.3) 418 (130–394) 0 (−0.08) 3.68 (2.5–7.4) 1.77 (1.2–3.4) 1.19 (0.2–0.9) 3.21 (0.1–1.3) 0.06 (−0.08)
Dog 11 6.11.13 42 (42–55) 13.4 (4.7–11.3) 231 (130–394) 0 (−0.08) 6.06 (2.5–7.4) 4.75 (1.2–3.4) 0.85 (0.2–0.9) 1.62 (0.1–1.3) 0.13 (−0.08)
Dog 12 24.10.13 46 (38–55) 19.0 (6.0–12.0) 159 (150–500) 10.17 (3.0–10.0) 7.24 (1.0–4.0) 0.61 (0–1.2) 0.95 (0–0.6) 0.04 (−0.04)
Dog 13 12.11.13 38 (42–55) 11.4 (4.7–11.3) 250 (130–394) 0.06 (0 – 0.08) 2.23 (2.5–7.4) 2.4 (1.2–3.4) 0.51 (0.2–0.9) 6.11 (0.1–1.3) 0.11 (−0.08)
Total
(%)
Increased 8/13 (62 %) 3/13 (23 %) 1/10 (10 %) 6/11 (55 %) 2/12 (17 %) 5/12 (42 %) 8/11 (73 %) 3/11 (27 %)
Decreased 9/13 (69%) 2/13 (15 %) 2/13 (15 %) 2/11 (18 %) 4/12 (33 %) 2/11 (18 %)
Values outside the reference range are shown in bold
1CDV positive dogs (at first presentation) are shown in bold, no samples could be collected from Dog 14 (not shown) due to aggressive behaviour; 2PCV packed cell volume; 3Reference range; 4Leuc leucocytes; 5Plat
platelets; 6Band Neutro banded neutrophils; 7Segm Neutro segmented neutrophils; 8Lymph lymphocytes; 9Mono monocytes; 10Eos eosinophils; 11Baso basophils
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Table 3 Blood biochemistry results of 13 rescue dogs at first presentation
Dog1 Date Bil2 (Ref3)
μmol/l
Urea (Ref3) mmol/l Crea4 (Ref3) μmol/l TP5 (Ref3) g/l Alb6 (Ref3) g/l AP7 (Ref3) U/l ALAT8 (Ref3) U/l Na9 (Ref3) mmol/l K10 (Ref3) mmol/l P11 (Ref3) mmol/l
Dog 1 28.10.13 0.6 (−3.5) 4.4 (3.8–5.9) 50 (50–119) 57 (56–71) 30 (29–37) 25 (20–98) 23 (20–93) 152 (152–159) 4.3 (4.3–5.3) 1.13 (1–1.6)
Dog 2 5.11.13 0.6 (−3.5) 2.6 (1.6–6.2) 44 (19–79) 58 (56–71) 29 (29–37) 38 (4–252) 28 (20–93) 153 (152–159) 4.6 (4.3–5.3) 1.89 (1.1–2.5)
Dog 3 23.10.13 2.5 (−3.9) 3.4 (3.3-10.8) 44 (52–177) 56 (56–73) 20 (30–41) 225 (9–132) 18 (26–126) 141 (142–154) 4.5 (4.2–5.4) 0.55 (0.9–1.9)
Dog 4 22.10.13 1.7 (−6.8) 3.8 (2.5–8.8) 84 (−133) 58 (54–68) 31 (30–37) 297 (−240) 63 (0–75) 146 (140–155) 4.7 (3.9–5.4) 1.1 (1.0–1.7)
Dog 5 5.11.13 0.2 (−3.5) 2.9 (1.6–6.2) 41 (19–79) 49 (56–71) 21 (29–37) 115 (4–252) 24 (20–93) 150 (152–159) 5.7 (4.3–5.3) 2.6 (1.1–2.5)
Dog 6 5.11.13 1.1 (−3.5) 4.2 (1.6–6.2) 57 (19–79) 49 (56–71) 27 (29–37) 132 (4–252) 29 (20–93) 151 (152–159) 4.7 (4.3–5.3) 1.75 (1.1–2.5)
Dog 7 5.11.13 0.2 (−3.5) 2.3 (1.6–6.2) 45 (19–79) 54 (56–71) 27 (29–37) 94 (4–252) 36 (20–93) 152 (152–159) 5.1 (4.3–5.3) 1.93 (1.1–2.5)
Dog 8 23.10.13 7.0 (−10) 7.0 (2.5–8.9) 94 (27–124) 73 (54–82) 33 (25–44) 108 (20–150) 46 (10–118) 143 (138–160) 5.9 (3.7–5.8) 1.84 (0.9–2.1)
Dog 9 6.11.13 1.3 (−3.5) 5.6 (3.8–5.9) 84 (50–119) 60 (56–71) 34 (29–37) 35 (20–98) 29 (20–93) 154 (152–159) 4.8 (4.3–5.3) 1.6 (1–1.6)
Dog 10 7.11.13 0.3 (−3.5) 2.9 (3.8–5.9) 58 (50–119) 64 (56–71) 26 (29–37) 60 (20–98) 26 (20–93) 153 (152–159) 5.0 (4.3–5.3) 1.8 (1–1.6)
Dog 11 6.11.13 1.4 (−3.5) 6.7 (3.8–5.9) 69 (50–119) 62 (56–71) 35 (29–37) 40 (20–98) 23 (20–93) 152 (152–159) 5.4 (4.3–5.3) 1.92 (1–1.6)
Dog 12 24.10.13 2.5 (−5.4) 6.2 (2.8–10.7) 103 (−133) 64 (52–71) 30 (26–37) 138 (0–121) 79 (−115) 151 (143–152) 4.7 (3.9–5.4) 1.4 (0.9–2)
Dog 13 12.11.13 1.6 (−3.5) 4.3 (3.8–5.9) 101 (50–119) 59 (56–71) 31 (29–37) 34 (20–98) 31 (20–93) 152 (152–159) 4.7 (4.3–5.3) 1.8 (1–1.6)
Total (%) Increased 1/13 (8 %) 3/13 (23 %) 3/13 (23 %) 4/13 (31 %)
Decreased 1/13 (8 %) 3/13 (23 %) 5/13 (39 %) 1/13 (8 %) 3/13 (23 %) 1/13 (8 %)
Values outside the reference range are shown in bold
1CDV positive dogs (at first presentation) are shown in bold, no samples could be collected from Dog 14 (not shown) due to aggressive behaviour; 2Bil bilirubin; 3Ref reference range; 4Crea creatinine; 5TP total protein;
6Alb albumin; 7AP alkaline phosphatase; 8ALAT alanine aminotransferase; 9Na sodium; 10K potassium; 11P phosphorus
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of the CDV isolates of the ten rescue dogs (Fig. 3) and
most closely related to the CDV vaccine strain Onderste-
poort (99 % nucleotide identity to AB250738).
Sequencing of the HA gene of CDV isolates of
five of the infected dogs revealed that the dogs were
infected with a similar CDV strain (99.9–100 % nu-
cleotide identity among the HA gene of CDV iso-
lates of Dogs 1, 5, 6 and 10); the HA gene of the
CDV isolate of Dog 9 differed in only one nucleo-
tide position from the HA gene sequences of the
other four CDV isolates. The phylogenetic analysis
revealed that the isolates from the five import dogs
belonged to the Arctic-like lineage of CDV (Fig. 4).
The HA gene sequences of the CDV isolates were
most similar to a published HA gene sequence of
a CDV strain from a domestic dog from Italy
(KF914669, 99 % nucleotide identity, Fig. 4) [18].
They were only distantly related to CDV strains iso-
lated during a CDV epidemic in wild carnivores in
Switzerland (JF810109 and JF810111, 92.6 % nucleotide
identity, Fig. 4)
CDV follow-up
Overall, two dogs (Dogs 5 and 11) exhibited CDV PCR-
negative results one month after the initial examination
(Table 4). Two months after the initial examination, an-
other three dogs were found to be CDV PCR-negative
(Dogs 7 to 9); three months after the initial examination,
Dog 3 was CDV-negative and the remaining three dogs
tested CDV-negative four months (Dog 6) and five
months (Dogs 1 and 2) after the initial examination
(Table 4).
Results for CPV and vector-borne infections
All twelve dogs that were tested for CPV at the initial
presentation were PCR-negative (Table 5). Vector-borne
infections were detected in 4 dogs (31 %, Table 5): infec-
tion with Babesia spp. was detected in Dogs 3 and 8; in-
fection with L. infantum was diagnosed in Dog 4 and
infection with Dirofilaria immitis was found in Dog 13.
Dog 13, which tested positive in D. immitis antigen and
Knott tests, had received a certificate from a laboratory
in Budapest, Hungary, that stated a negative result in the
Knott test in August 2013. None of the rescue dogs
tested positive for Ehrlichia canis (Table 5).
Therapy, clinical course and outcome
The CDV-infected Dogs 1, 3 and 4 were hospitalized for
two to three days and received intravenous infusions of
crystalloids, intravenous antibiotic therapy and inhal-
ation (Table 1). Dog 3, which was co-infected with
Babesia spp., was treated with two imidocarb injections
two weeks apart. Dog 4, which was co-infected with
L. infantum was treated using allopurinol. All three dogs
Table 4 CDV PCR results at first presentation and at different time points thereafter in 13 rescue dogs
Dogs1 Date of first
investigation
CDV real-time RT-qPCR results2
At first investigation After 1 month After 2 months After 3 months After 4 months After 5 months
CS NS Blood CS/NS/OC6 CS NS OC CS NS OC CS NS OC CS NS OC
Dog 1 28.10.13 pos pos pos pos pos neg pos pos neg neg neg neg
Dog 2 5.11.13 pos pos pos pos neg pos neg neg pos neg neg neg neg
Dog 3 6.11.133 pos neg pos pos neg neg neg
Dog 4 22.10.13 pos
Dog 5 5.11.13 pos pos pos neg
Dog 6 5.11.13 pos pos pos pos pos pos neg pos neg neg neg neg neg
Dog 7 5.11.13 neg pos pos quest7 neg neg neg
Dog 8 6.11.134 pos pos neg pos neg neg neg
Dog 9 6.11.13 pos neg pos neg neg neg
Dog 10 7.11.13 pos neg neg pos pos pos pos pos pos neg
Dog 11 6.11.13 pos neg neg neg
Dog 12 12.11.135 neg neg
Dog 13 12.11.13 neg neg neg
Total positive 11/13 7/10 2/5 4/5 2/3 0/2
Positive results are shown in bold
1CDV PCR-positive dogs (at first investigation) are shown in bold, no samples could be collected from Dog 14 (not shown) due to aggressive behaviour. 2CS
conjunctival swab, NS nasal swab, OC oropharyngeal swab, pos positive result, neg negative result, quest questionable result. 3Dog 3 had already tested CDV
PCR-positive in a CS collected at first presentation (23.10.13) by the private veterinarian. 4Samples for CDV PCR were collected for the first time two weeks after
first presentation (23.10.13). 5Dog 12 had already tested CDV PCR-negative in blood collected by the private veterinarian at first presentation (24.10.13). 6Conjunctival,
nasal and oropharyngeal swabs were pooled for CDV PCR. 7PCR result questionable due to low cGAPDH levels (for details, see Methods section)
Willi et al. BMC Veterinary Research  (2015) 11:154 Page 7 of 15
Table 5 Results for CPV and for vector-borne infections in 13 rescue dogs
Dog1 Date of sampling CPV2,3 Babesia spp.2 Ehrlichia canis2 Leishmania infantum2 Dirofilaria immitis2
Dog 1 28.10.13 neg neg 5 neg 8 neg 10 neg 12
Dog 2 05.11.13 neg neg 5 neg 8 neg 10 neg 12
Dog 3 25.10.13 pos4
06.11.13 neg pos5 neg 8 neg 10 neg 12
Dog 4 22.10.13 neg 4 neg 9 pos11
Dog 5 5.11.13 neg neg 5 neg 8 neg 10 neg 12
Dog 6 5.11.13 neg neg 5 neg 8 neg 10 neg 12
Dog 7 5.11.13 neg neg 5 neg 8 neg 10 neg 12
Dog 8 23.10.13 pos6
6.11.13 neg pos5 neg 8 interm10 neg 12
Dog 9 6.11.13 neg neg 5 neg 8 neg 10 neg 12
Dog 10 7.11.13 neg neg 5 neg 8 neg 10 neg 12
Dog 11 6.11.13 neg neg 5 neg 8 neg 10 neg 12
Dog 12 24.10.13 interm7 neg 8 neg 10 neg 13
12.11.13 neg
Dog 13 12.11.13 neg neg 4 neg 8 neg 10 pos12,14
Total positive (%) 0/12 (0 %) 2/13 (15 %) 0/13 (0 %) 1/13 (8 %) 1/13 (8 %)
Positive results are shown in bold
1CDV-positive dogs (at first presentation) are shown in bold; no samples could be collected from Dog 14 (not shown) due to aggressive behaviour; 2pos positive,
neg negative, interm intermediate result, 3Result of CPV real-time qPCR; 4Microscopic evaluation of blood smears for the presence of Babesia spp. organisms by the
private veterinarian (Dog 3) or a commercial laboratory (Dog 4: Alomed, Radolfzell-Böhringen, Germany); 5Commercial immunofluorescence antibody test (IFAT)
for detecting anti-Babesia canis antibodies (MegaFLUO® BABESIA canis, Megacor Diagnostik GmbH, Hörbranz, Austria) performed by the Institute of Parasitology, Univer-
sity of Zurich; 6Babesia-specific PCR assay from blood performed by a commercial laboratory (Labor am Zugersee, Hünenberg, Switzerland); 7Enzyme-linked
immunosorbent assay (ELISA) for the detection of B. canis antibodies performed by a commercial laboratory (IDEXX Diavet AG, Bäch, Switzerland); 8Commercial IFAT for
detecting immunoglobulin G antibodies against Ehrlichia canis (Mega Screen Fluoehrlichia canis, Megacor GmbH) performed by the Clinical Laboratory, University of Zur-
ich; 9PCR for detecting E. canis from blood performed by a commercial laboratory (Alomed); 10Published ELISA for the specific detection of anti-Leishmania IgG
antibodies [45] performed by the Institute of Parasitology, University of Zurich, using Leishmania infantum promastigote stage antigens and goat anti-dog IgG (γ)
antibodies conjugated to alkaline phosphatase (Kirkegaard and Perry Lab, Inc., Maryland, USA); 11IFAT for detecting anti-L. infantum antibodies performed
by a commercial laboratory (Alomed); 12commercial Dirofilaria immitis antigen detection test (DiroCHECK, Synbiotics, Lyon, France) performed by the
Institute of Parasitology, University of Zurich; 13ELISA for the detection of D. immitis antigen performed by a commercial laboratory (IDEXX Diavet AG);
14Knott Test for the detection of microfilaria of D. immitis performed by the Institute of Parasitology, University of Zurich, as previously published [46]
Fig 2 Diagnostic imaging of the thorax of Dog 2. a Right to left lateral, (b): ventrodorsal, and (c): close-up of the lateral projection in the caudodorsal
lung field of Dog 2 showing a generalized, moderate, mildly heterogeneous increase in pulmonary opacity, numerous thickened bronchial ring
shadows and reduced delineation of the peripheral pulmonary vessels. These generalized moderate broncho-interstitial lung changes are compatible
with a moderate bronchopneumonia or bronchitis
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showed rapid clinical improvement with treatment and
were discharged with oral antibiotic therapy. Repeated
haematological examination in Dog 3 two weeks later re-
vealed that the pancytopenia had resolved and had
returned to moderate neutrophilia, eosinophilia and
slight monocytosis. Mild anaemia was still present in
Dog 3 at that time (data not shown). Repeated haematology
in Dog 4 two weeks after the initial presentation
showed normal platelets counts and nearly normal PCV
values (data not shown). All three dogs were clinically
asymptomatic in the 6-month follow-up period.
Dog 2 was ambulatory and was treated with oral anti-
biotics and antibiotic eye drops (Table 1). The dog
showed several relapses with purulent nasal and ocular
discharge after antibiotic therapy ceased and was repeat-
edly treated with antibiotics for two months. Thereafter,
there was no relapse, and the dog was clinically asymp-
tomatic in the remaining 4-month follow-up period.
Five CDV PCR-positive dogs (Dogs 5 to 8 and 10) re-
ceived oral antibiotic therapy (amoxicillin clavulanic acid
or doxycycline) for seven to ten days after their arrival in
Switzerland. Dog 5 developed watery diarrhoea two
weeks after arrival and was additionally treated with
metronidazole, deworming and a highly digestible diet.
Dog 8, which was co-infected with Babesia spp., received
two injections of imidocarb diproprionate two weeks
apart and antibiotic ear drops because of otitis externa.
At the end of the 6-month follow-up period, all of the
CDV PCR-positive dogs had recovered and none had
developed neurological signs.
Confinement of infection
All of the owners of the CDV PCR-positive dogs were
instructed by the first author (BW) to quarantine the
dogs until they tested CDV PCR-negative. The owners
of the CDV-positive dogs in multidog households (Dogs
3, 6, 7, 8 and 9) were instructed to separate the infected
dog from the other dogs in the household. However, sev-
eral dogs (Dogs 6, 7, 8 and 9) had already had contact
with adult dogs within the household at the time when
the CDV diagnosis was made. All of the contact dogs
had been vaccinated against CDV, although several dogs
had only received the initial vaccination series as puppies
and had received no booster vaccinations (data not
shown). Two dogs that were in close contact with Dogs
7 and 9 were tested for the CDV infection with PCR one
month and two months after the initial CDV diagnosis
in Dogs 7 and 9. One contact dog exhibited a single,
very weak CDV-positive result in the conjunctival swab
in the first sampling but was negative in all of the swabs
collected one month later (data not shown). The other
contact dog tested PCR-negative in all of the collected
samples (data not shown). In all of the other multidog
households, no samples were collected for CDV PCR,
but no clinical signs of the disease were noted in the 6-
month follow-up period.
Discussion
The present study describes a distemper outbreak in
rescue dogs in Switzerland that had been imported by
an animal welfare organization. One dog had to be
Fig. 3 Sequence alignment of CDV vaccine strains and CDV isolates of the rescue dogs. The sequence alignment of the M gene and M-F intergenic
region of three CDV vaccine strains (contained in Nobivac® DHHPi, MSD Animal Health; Canigen® SHA2PPi, Virbac; and Biocan® DHPPi & L, Bioveta) and
of ten wild-type CDV isolates of the rescue dogs (Dogs 1 to 3 and 5 to 11) is shown. Grey-shaded letters: identical nucleotides between vaccine strains
and wild-type isolates. Black letters: nucleotides that differ between vaccine strains and wild-type isolates. Grey bars: schematic drawing depicting the
positions of the primers and the probe used in the CDV vaccine specific real-time RT-qPCR assay [17]. Consensus: Consensus sequence of 100 %
identical bases matching all of the sequences (most of the ambiguities)
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euthanized directly after import for humane reasons,
whereas nine dogs required therapy for up to two
months; three of these dogs were hospitalized at veterinary
clinics. The imported animals shed CDV for up to four
months, which necessitated long-term quarantine
measures. Moreover, four of the dogs were infected with
vector-borne pathogens.
The present study underscores the risk of introdu-
cing contagious or vector-borne pathogens to central
European countries by importing rescue dogs with in-
complete vaccination. Based on the data of the ANIS
in Switzerland, 43.9 % of the newly registered dogs in
2012 were imported [16]. The imported dogs primar-
ily comprised small and miniature purebred dogs to
meet the increasing demand for these types of breeds
in Switzerland, and mixed breed dogs that are rescued
by animal welfare organisations [16]. The dogs of
both groups are at risk for carrying infectious diseases
because of the inadequate vaccination policies and
quarantine measures in many breeding kennels and
animal shelters in Eastern Europe. In the animal shel-
ter in Hungary where the dogs originate, no quaran-
tine measures or reliable vaccination policies had
been implemented. The dogs had only received a sin-
gle CDV vaccination either one week or one month
before importation to Switzerland. At this time point,
several dogs had likely been infected with CDV. After
the outbreak, the rescue organisation was instructed
to introduce vaccination policies and quarantine measures
within the animal shelter.
In Switzerland, the vaccination rate in dogs is insuffi-
ciently high to provide population immunity against the
CDV infection. The proportion of vaccinated dogs in a
population must be > 70 % to provide protection for the
dog population, in contrast to protection of only a single
vaccinated dog [19]. A vaccination rate of 60–70 % has
been estimated for Swiss dogs based on the numbers of
sold vaccine doses in 2009 [20]. Mandatory courses for
new dog owners have been introduced in Switzerland in
which freshly adopted dogs come in close contact with
each other. Together with the decreasing vaccination
rate and the increasing number of imported dogs, this
situation has clearly increased the risk for canine distem-
per outbreaks. Dog owners and animal welfare organisa-
tions should be informed concerning the critical
importance of complete vaccination schedules in domestic
dogs. In the present outbreak, the infection could be pre-
vented from spreading to other dogs by extensive follow-
up examinations of the dogs and a thorough education of
the dog owners concerning the critical importance of
strict quarantine measures. Luckily, no CDV-positive dogs
of this study had already had contact with young unvac-
cinated dogs at the time of diagnosis. The CDV vaccines
are known to induce a strong and long-lasting immunity
when no interference with maternally derived antibodies
occurs [21, 22].
CDV was reported to be shed by infected animals for
up to three months [11, 23]. We demonstrated CDV
shedding in some dogs in the present study even for up
to four months. Shedding was detected for several
months after the cessation of clinical disease. Our results
underscore the role of asymptomatic carriers in CDV
epidemiology and the importance of a long-term follow-
up of CDV-positive dogs for preventing the spread of in-
fection. Several studies have reported the excretion of
vaccine strains after CDV vaccination [11, 24]. This was
not observed in the present study: the dogs that tested
CDV PCR-positive were shown to be infected with wild-
type CDV, although the majority of the dogs had re-
ceived MLV CDV vaccination within one to seven weeks
before PCR testing. Consistent with the published data
[25], PCR from conjunctival swabs was found to be most
reliable for detecting CDV in acutely infected animals
and during follow-up examinations. However, in one
animal, only the nasal but not the conjunctival swab
tested positive for CDV.
Nine of the dogs in the present study were hospitalized
or required ambulatory therapy for up to two months.
Another animal was euthanised directly after import
because of clinical deterioration. In all of the affected dogs,
the respiratory and gastrointestinal symptoms predomi-
nated. In four dogs, signs of bronchopneumonia were
evident. Remarkably, none of the dogs developed a neuro-
logical disease. Whether the latter was due to the intrinsic
properties of the CDV strain or to the age and immune
status of the dogs is unknown. The sequence analyses of
the CDV strains detected in the rescue dogs indicated that
all of the dogs were infected with the same wild-type CDV
strain, which belongs to the Arctic-like lineage of CDV
[18, 26]. The initial description of Arctic-like lineage of
CDV dates back to the late 1980s, when epizootics were
observed in seals in Northern Europe and Siberia [27–29].
(See figure on previous page.)
Fig. 4 Phylogenetic relationship between selected CDV strains based on the complete haemagglutinin (HA) gene sequence. The CDV isolates
analysed in this study appear in bold. Nine CDV lineages are shown: Asia-1, Europe, America-2, Europe-Wildlife, Africa, Arctic-like, Asia-2, Asia-3
and America-1. Phocine distemper virus (PDV-1) was used as the outgroup. GenBank accession numbers, host species and geographical origin are
indicated, if known. The numbers at the nodes were generated from 1000 bootstrap resamplings; only values > 70 are shown. The bar represents
the mean number of differences per 200 sites. Strain AF178038 (giant panda isolate) is the resultant of a genetic recombination between “Asia-1”
and a “Europe-Wildlife” strain [44]
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The strains of the Arctic-like lineage are closely related to
the CDV strains in North America, China and Greenland
and were recently isolated from domestic dogs in Hungary
[30] and domestic dogs and wolves in Southern Italy
[31, 32]. The present study shows how fast these strains
can spread to central European countries by import of
infected domestic dogs.
The present study indicates that rescue dogs may also
play an important role in the spread of vector-borne in-
fections to central European countries. Babesia spp., L.
infantum or D. immitis infections were detected in four
of the 13 rescue dogs. Several dogs were reported to be
free of these pathogens based on the laboratory certifi-
cates provided by the animal welfare organisation. In the
case of Dog 13, D. immitis infection was diagnosed in
this study using the antigen enzyme immunoassay and
the Knott test in November 2013. The dog was found to
be negative in the Knott test in August 2013. The D.
immitis antigen and Knott tests are known to turn posi-
tive not before five to eight months after infection [33];
therefore, the infection could have been missed in the
first testing. L. infantum serology specimen, which was
positive in Dog 4, has similar limitations in that negative
serological results cannot exclude infection and serocon-
version can occur many months after infection [34]. Fu-
ture dog owners should be properly informed concerning
the limitations of these tests and the costs of treatment for
vector-borne infections.
Conclusion
The present study highlights the risks of spreading con-
tagious viral and vector-borne infections by a non-
selective import of sick and unvaccinated dogs or dogs
with incomplete vaccination from Eastern European
countries. The animal welfare organisations should be
thoroughly informed concerning the critical importance
of complete vaccination schedules and quarantine mea-
sures in animal shelters to combat the outbreaks and the
spread of viral pathogens to other countries. Dog owners
in Switzerland should be educated regarding the risk of
and the potential costs of adopting sick dogs or dogs
with incomplete vaccination and the critical import-
ance of sufficiently high vaccination rates in domestic
dogs in Switzerland.
Methods
Study design
The present study describes a distemper outbreak in
fifteen dogs originating from an animal shelter in
Kecskemét, Hungary, and the prospective follow-up of
the infected animals. The dogs were imported to
Switzerland by an animal welfare organisation on October
22, 2013. One dog had to be euthanised within a several
days of arrival. No data on that dog were available. Of the
remaining fourteen dogs, the signalment, vaccination and
medical history and clinical signs were recorded (Table 1)
and dogs were monitored for six months.
Sample and data collection and sample processing
Within three weeks of arrival, a clinical examination was
performed in 13 of the 14 dogs at the small animal
clinics of the Vetsuisse Faculty, University of Zurich
(Dogs 1 and 2) or Bern (Dog 3), by a private veterinarian
(Dogs 4, 8 and 12) or by the first author (BW) during a
visit of the dogs at their private homes (Dogs 5 to 7, 9 to
11 and 13, Table 1). No clinical examination or sample
collection was possible in Dog 14 because of aggressive
behaviour. In five dogs (Dogs 1 to 4 and 13), radio-
graphic examinations of the thorax were performed at
the small animal clinic of the Vetsuisse Faculty of Zurich
(Dogs 1, 2 and 13), of the Vetsuisse Faculty of Bern (Dog
3), or by a private veterinarian (Dog 4). In Dog 13, echo-
cardiography was performed at the division of cardiology,
Vetsuisse Faculty, University of Zurich.
Nasal and/or conjunctival swabs were collected from
13 dogs for CDV-specific real-time RT-qPCR and rectal
swabs from 12 dogs for CPV real-time qPCR as indi-
cated in Tables 4 and 5. EDTA blood and serum samples
were collected to obtain haematology and blood bio-
chemistry results, and for CDV real-time RT-qPCR and
testing for vector-borne infections (Babesia spp., E.
canis, L. infantum and D. immitis) as indicated in Ta-
bles 2 through 5. All of the samples were processed
within 12 h of collection. In 10 of the 11 CDV-infected
dogs (Dogs 1 to 3 and 5 to 11), monthly follow-up ex-
aminations for CDV were performed from conjunctival,
nasal and oropharyngeal swabs (Table 4). The swabs
were collected by the owner based on written and image
instructions regarding how to collect and ship the sam-
ples. All of the swabs were sent by priority mail to the
Clinical Laboratory, Vetsuisse Faculty, University of
Zurich, within one day of collection. Follow-up was con-
tinued in each dog until the dog tested CDV PCR-
negative, except for Dog 10, in which the owner declined
further testing despite a PCR-positive result at three
months of follow-up.
Haematology and blood biochemistry
Haematology and blood biochemistry tests were per-
formed at the Clinical Laboratory, Vetsuisse Faculty,
University of Zurich (Dogs 1 and 2, 5 to 11 and 13), at
the Clinical Diagnostic Laboratory, Vetsuisse Faculty,
University of Bern (Dog 3), at a private laboratory (Dog
4: Alomed, Radolfzell-Böhringen, Germany) or by a pri-
vate veterinarian (Dog 8, Tables 2 and 3). The labora-
tory’s own device-specific reference intervals were
applied; for dogs aged 6 to 8 months (Dogs 2, 5 to 7),
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published reference intervals for phosphorous, alkaline
phosphatase, urea and creatinine were used [35].
Total nucleic acid (TNA) extraction
At the time of the initial examinations, conjunctival,
nasal or rectal swabs were incubated for 10 min in
300 μl of phosphate buffered saline (PBS) at 40 °C; the
swabs were subsequently turned upside down and cen-
trifuged for 1 min at 6440 × g and the supernatant was
used for TNA extraction (see below). For the follow-up
examinations, the two conjunctival and the two nasal
swabs, respectively, were pooled in a total of 400 μl of
PBS before incubation at 40 °C for 10 min and TNA ex-
traction. The TNA extraction was performed from
100 μl of EDTA blood, 200 μl of swab supernatant or
vaccine material that was resuspended in 500 μl of PBS
(see below) using the MagNa Pure LC (Roche Diagnos-
tics AG, Rotkreuz, Switzerland) and the MagNa Pure LC
TNA Isolation Kit (Roche Diagnostics) following the
manufacturer’s instructions. With each batch of extrac-
tion, a negative control consisting of 200 μl of PBS was
used to monitor for cross-contamination. The TNA was
stored at −80 °C until PCR analysis was performed.
PCR assays and sequencing
For CDV testing, a published real-time RT-qPCR assay
was used as previously described [36]. For the detection
of CPV, a published real-time qPCR assay developed for
the detection of feline parvovirus (FPV) was applied
[37]. The assay amplifies a 107 bp sequence of the highly
conserved VP1/VP2 gene region using the following
primers and probe: PV3294f: 5′-ACTGCATCATTGAT
GGTTGCA-3′; PV3400r: 5′-GGTATGGTTGGTTTC
CATGGA-3′ PV3375p: 5′-FAM-CCCAATGTCTCAGA
TCTCATAGCTGCTGG-6-TAMRA-3′. Sequence com-
parison revealed that the primer and probe-binding sites
in the VP1/VP2 gene region of FPV and CPV showed >
99 % sequence identity (GenBank accession numbers
M38246, M38245, M19296, M74849, M74852, M24000,
M24003, KM457142, JQ268284). During CDV follow-up,
a published canine (c)GAPDH PCR assay was applied to
ensure that the quality of the swabs collected by the dog
owners was adequate [38]. During follow-up, dogs were
stated CDV-negative if they tested PCR-negative for
CDV in conjunctival, nasal and oropharyngeal swabs
and the swabs showed a cGAPDH threshold cycle
below 32. All of the real-time PCR reactions were
run using an ABI 7500Fast Real-Time PCR system
(Applied Biosystems, Rotkreuz, Switzerland). Negative
and positive controls were included in each PCR run.
To ensure that the CDV real-time RT-qPCR signal
was due to infection and was not due to a recent vaccin-
ation, a published real-time RT-qPCR system based on
the CDV M gene and M-F intergenic region was used
[17]. The primers of the PCR assay amplify the MLV
vaccine and wild type CDV strains, whereas the probe of
the assay only binds to the MLV vaccine strains (Fig. 3).
Because no sequence data have been published on the
M gene and the M-F intergenic region of CDV U39
strain contained in the vaccine used in the rescue dogs
(Biocan® DHPPi & L, Bioveta), the latter vaccine, to-
gether with two other CDV vaccines that are commer-
cially available in Switzerland (Nobivac® DHHPi, MSD
Animal Health; Canigen® SHA2PPi, Vibac) were tested
to confirm that the CDV strains contained in these
vaccines are detected by the assay. The TNA from
the three vaccines and from the conjunctival or nasal
swabs from 10 of 11 CDV PCR-positive dogs (Dogs 1
to 3 and 5 to 11) were subjected to real-time RT-
qPCR. The PCR products were separated using 2.5 %
agarose gel and appropriate-sized bands (294 bp) cut
out, extracted using the MinElute® Gel extraction kit
(Qiagen, Hombrechtikon, Switzerland) and sequenced
(Microsynth, Balgach, Switzerland).
The complete haemagglutinin (HA) genes of the CDV
isolates from five dogs were sequenced (Dogs 1, 5, 6, 9
and 10). The TNA extracted from the conjunctival swabs
was used as a template. For amplification, five previously
published primer pairs were used [39]; single nucleotides
in one primer pair (472f and 1172r) had to be changed
because of mismatches within the primer binding sites
for the five CDV isolates (472f_new: 5'- CTGTACAT
CACCAAGTCATA-3' and 1172r_new: 5'-TAGAATAC
CATCTTGTGAAT-3'). Reverse transcription was per-
formed using the High Capacity cDNA reverse tran-
scription kit (Applied Biosystems) according to the
manufacturer’s instructions. The PCR amplification was
conducted using 5 μl of 5 x HF PCR buffer (Finnzymes,
BioConcept, Allschwil, Switzerland), 500 nM each pri-
mer, 200 μM each dNTP (Sigma-Aldrich, Buchs,
Switzerland), 1 U Phusion High-Fidelity DNA Polymer-
ase (Finnzymes), and 2.5 μl template cDNA made up to
25 μl with water. The thermal cycling conditions com-
prised 98 °C for 2 min, 35 cycles at 98 °C for 30 s, 50 °C
for 30 s, 65 °C for 1 min, and a final elongation at 72 °C
for 3 min. After the PCR run, the amplification products
were separated using 2 % agarose gel; appropriately sized
products were excised and purified using the MinElute
Gel Extraction Kit (Qiagen). Direct sequencing of the
purified amplicons was performed using the amplifica-
tion primers in a commercial laboratory (Microsynth,
Balgach, Switzerland) under standard conditions.
Testing for vector-borne infections
Vector-borne infections were tested in 13 dogs, as
shown in Table 5. The analyses were performed at the
Clinical Laboratory (for E. canis) and the Institute of
Parasitology (for Babesia spp., L. infantum and D. immitis)
Willi et al. BMC Veterinary Research  (2015) 11:154 Page 13 of 15
of the Vetsuisse Faculty, University of Zurich, and at pri-
vate laboratories (Dog 8: Labor am Zugersee, Hünenberg,
Switzerland; Dog 4: Alomed; Dog 12: IDEXX Diavet AG,
Bäch, Switzerland) (Table 5). The laboratories’ own refer-
ence values were used for defining the positive, negative
and intermediate results. The microscopic blood smear
evaluation for the presence of Babesia spp. organisms was
conducted in Dog 3 by the private veterinarian and in Dog
4 by a commercial laboratory (Alomed) (Table 5).
Sequence editing and phylogenetic analyses
The obtained sequences were edited and aligned with a
consensus sequence using Geneious Version 7.1.8 [40].
Only the nucleotides available for all of the included se-
quences (2005 nucleotides of the HA gene) were used to
calculate the percent nucleotide identities and perform
the phylogenetic analyses. For the phylogenetic analyses,
the sequences were aligned with known distemper
sequences from GenBank (see Fig. 4) using Geneious
Version 7.1.8. A bootstrap phylogenetic tree demonstrat-
ing the relationship between the isolates was created
using the maximum-likelihood method [41] and a dis-
tance matrix corrected for nucleotide substitutions based
on the Kimura 2-parameter model [42]. The dataset was
resampled 1000 times to generate bootstrap values. The
phylogenetic and molecular evolutionary analyses were
conducted using the MEGA version 6 [43].
Nucleotide sequence accession numbers
Nucleotide sequences obtained in this study have
been submitted to GenBank under accession numbers
KR002657 to KR002671.
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